A Randomised, Double-Blind, Placebo-Controlled Trial Evaluating Concentrated Phytochemical-Rich Nutritional Capsule in Addition to a Probiotic Capsule on Clinical Outcomes among Individuals with COVID-19—The UK Phyto-V Study

Thomas, Robert; Williams, M.; Aldous, Jeffrey William Frederick; Yanagisawa, Yuuki; Kumar, Rajeev; Forsyth, Rachel; Chater, Angel M.

doi:10.3390/covid2040031

Cited by 11 publications

(11 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A small trial of sulodexide in individuals with endothelial dysfunction saw a reduction in symptom severity 169 . Pilot studies of probiotics indicated potential in alleviating gastrointestinal and non-gastrointestinal symptoms 170 , 171 . Two patients with long COVID experienced substantial alleviation of dysautonomia symptoms following stellate ganglion block 172 .…”

Section: Diagnostic Tools and Treatmentsmentioning

confidence: 99%

Long COVID: major findings, mechanisms and recommendations

Davis¹,

McCorkell²,

et al. 2023

View full text Add to dashboard Cite

Long COVID is an often debilitating illness that occurs in at least 10% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. More than 200 symptoms have been identified with impacts on multiple organ systems. At least 65 million individuals worldwide are estimated to have long COVID, with cases increasing daily. Biomedical research has made substantial progress in identifying various pathophysiological changes and risk factors and in characterizing the illness; further, similarities with other viral-onset illnesses such as myalgic encephalomyelitis/chronic fatigue syndrome and postural orthostatic tachycardia syndrome have laid the groundwork for research in the field. In this Review, we explore the current literature and highlight key findings, the overlap with other conditions, the variable onset of symptoms, long COVID in children and the impact of vaccinations. Although these key findings are critical to understanding long COVID, current diagnostic and treatment options are insufficient, and clinical trials must be prioritized that address leading hypotheses. Additionally, to strengthen long COVID research, future studies must account for biases and SARS-CoV-2 testing issues, build on viral-onset research, be inclusive of marginalized populations and meaningfully engage patients throughout the research process.

show abstract

Section: Diagnostic Tools and Treatmentsmentioning

confidence: 99%

Long COVID: major findings, mechanisms and recommendations

Davis¹,

McCorkell²,

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The results are promising and should prompt further longitudinal studies with more patients to investigate underlying pathomechanisms and changes in the microbiome of post-infectious fatigue patients. Especially in patients with Post-COVID19 conditions such studies will be helpful, as results of a recent study showed that the intervention with probiotics in combination with enzymes [ 55 ] or phyto preparations [ 56 ] was effective to reduce persistent symptoms and probiotic therapy during acute infection led to fewer symptoms compared to patients without such a treatment [ 57 ].…”

Section: Discussionmentioning

confidence: 99%

Positive Effects of Probiotic Therapy in Patients with Post-Infectious Fatigue

Obermoser,

Brigo,

Schroll

et al. 2023

Metabolites

View full text Add to dashboard Cite

Post-infectious fatigue is a common complication that can lead to decreased physical efficiency, depression, and impaired quality of life. Dysbiosis of the gut microbiota has been proposed as a contributing factor, as the gut–brain axis plays an important role in regulating physical and mental health. This pilot study aimed to investigate the severity of fatigue and depression, as well as the quality of life of 70 patients with post-infectious fatigue who received a multi-strain probiotic preparation or placebo in a double-blind, placebo-controlled trial. Patients completed questionnaires to assess their fatigue (fatigue severity scale (FSS)), mood (Beck Depression Inventory II (BDI-II)), and quality of life (short form-36 (SF-36)) at baseline and after 3 and 6 months of treatment. Routine laboratory parameters were also assessed, including immune-mediated changes in tryptophan and phenylalanine metabolism. The intervention was effective in improving fatigue, mood, and quality of life in both the probiotic and placebo groups, with greater improvements seen in the probiotic group. FSS and BDI-II scores declined significantly under treatment with both probiotics and placebo, but patients who received probiotics had significantly lower FSS (p < 0.001) and BDI-II (p < 0.001) scores after 6 months. Quality of life scores improved significantly in patients who received probiotics (p < 0.001), while patients taking a placebo only saw improvements in the “Physical limitation” and “Energy/Fatigue” subcategories. After 6 months neopterin was higher in patients receiving placebo, while no longitudinal changes in interferon-gamma mediated biochemical pathways were observed. These findings suggest that probiotics may be a promising intervention for improving the health of patients with post-infectious fatigue, potentially through modulating the gut–brain axis.

show abstract

“…One study gave probiotic capsules to people experiencing GI and non-GI symptoms of covid for an average of 108 days. It found that those given the probiotic (but not the control group) showed a significant improvement in cough, fatigue, and overall wellbeing, as well as in GI symptoms 10…”

Section: Can a Healthy Microbiome Reduce Covid Severity?mentioning

confidence: 99%